Conventional to Early Phase Standardized Uptake Value Ratio on 18F FDG PET/CT Could Reflect Prognosis in Patients with Non-small Cell Lung Cancer

Objective: A high metabolism/perfusion rate in the tumor is known to be factor indicating poor prognosis. The goal of this study was to investigate the prognostic value of the ratio of the conventional standard uptake value to early-phase imaging standard uptake value in patients with newly diagnosed non-small cell lung cancer. Materials and Methods: Early-phase imaging was obtained in the first 120 seconds and conventional imaging was taken after median 66 minutes. The ratio of the conventional standard uptake value to earlyphase imaging standard uptake value was calculated. Univariate and multivariate analyses were performed using the Cox proportional hazards regression model to assess the relationship between progression-free survival and ratio of the conventional standard uptake value to early-phase imaging standard uptake. Results: A total of 77 patients with non-small cell lung cancer were recruited. Progression-free survival analysis was performed in 52 inoperable patients. Progression-free survival was found to be related to conventional standard uptake value (p

PDF

___

[1] Takeda A, Yokosuka N, Ohashi T et al. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized nonsmall-cell lung cancer after stereotactic body radiotherapy (SBRT). Radiother Oncol. 2011; 101: 291-7.

[2] Imamura Y, Azuma K, Kurata S et al. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. Lung Cancer. 2011; 71: 49-54.

[3] Kohutek ZA, Wu AJ, Zhang Z et al. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for nonsmall cell lung cancer. Lung Cancer. 2015; 89: 115- 20.

[4] Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002; 8: S62-S7.

[5] Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995; 36: 1625-32.

[6] Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 2007; 53: 233-56.

[7] Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004; 4: 437-47.

[8] Held KD. Radiobiology for the Radiologist, by Eric J. Hall and Amato J. Giaccia. Radiat Res. 2006; 166: 816-7.

[9] Servagi-Vernat S, Differding S, Sterpin E et al. Hypoxiaguided adaptive radiation dose escalation in head and neck carcinoma: a planning study. Acta Oncol. 2015; 54: 1008-16.

[10] Mullani N. et al. 9: 30—9: 45: First Pass FDG Measured Blood Flow in Tumors: A Comparison with O-15 Labeled Water Measured Blood Flow. Clinical Positron Imaging. 2000; 3: 153.

[11] Mullani NA, Herbst RS, O’Neil RG, et al. Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. J Nucl Med. 2008; 49: 517-23.

[12] Goethals I, Hanssens S, Kortbeek K, et al. Hypothesis using dynamic 18 F-FDG PET in oncology. Eur J Nucl Med Mol Imaging. 2010; 37: 833-833.

[13] Mertens J, Ham H, De AZ, et al. Tumor perfusion using firstpass F-18 FDG PET images. Clin Nucl Med. 2012; 37: 166-7.

[14] Komar G, Kauhanen S, Liukko K et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res. 2009; 15 : 5511-7.

[15] Hoekstra CJ, Stroobants SG, Hoekstra OS, et al. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H215O and positron emission tomography. Clin Cancer Res. 2002; 8 : 2109-15.

[16] van Elmpt W, Zegers CM, Reymen B, et al. Multiparametric imaging of patient and tumour heterogeneity in nonsmall-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. Eur J Nucl Med Mol Imaging. 2016; 43: 240-8.

[17] Carlson DJ, Yenice KM, Orton CG. Tumor hypoxia is an important mechanism of radioresistance in hypofractionated radiotherapy and must be considered in the treatment planning process. Med Phys. 2011; 38: 6347-50.

[18] Hermans R, Meijerink M, Van den Bogaert W, et al. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-andneck cancer after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57: 1351-6.

[19] Park M-S, Klotz E, Kim M-J et al. Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo-and radiation therapy. Radiology. 2009; 250: 110-7.

[20] Aoki M, Akimoto H, Sato M, et al. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/ computed tomography measurements on local control of non–small cell lung cancer treated with stereotactic body radiotherapy. J Radiat Res. 2016; 57: 533-40.

[21] Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002; 43: 500-9.

[22] Rusten E, Rødal J, Revheim ME, et al. Quantitative dynamic 18FDG-PET and tracer kinetic analysis of soft tissue sarcomas. Acta Oncol. 2013; 52: 1160-7.

[23] Okazumi S, Dimitrakopoulou-Strauss A, Schwarzbach M, et al. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis. Hell J Nucl Med. 2009; 12: 223-8.

[24] Strauss LG, Koczan D, Klippel S, et al. Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med. 2008; 49: 1238-44.

[25] TUNCEL, M., et al. Practical measures of dynamic 18 FDG time-activiy curves. Eur J Nucl Med Mol Imaging. 2015 (suppl 1): p. S375-S375.

[26] Miles K, Williams R. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging. 2008; 8: 81.

[27] Miles K, Charnsangavej C, Cuenod C. CT perfusion of lympth nodes. Multi-Detector Computed Tomography in Oncology. CRC Press; 2007. p. 179-88.

[28] Willett CG, Boucher Y, Di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10 : 145-7.

[29] Mankoff DA, Dunnwald LK, Gralow JR et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 2003; 44: 1806-14.

[30] Herbst RS, Mullani NA, Davis DW et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002; 20: 3804-14.

[31] Tateishi U, Nishihara H, Tsukamoto E et al. Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr. 2002; 26: 185-90.

[32] Miles KA, Griffiths MR, Keith CJ. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrastenhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging. 2006; 33: 22-8.

[33] Kiessling F, Boese J, Corvinus C et al. Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol. 2004; 14: 1226-33.

[34] Fukuda K, Taniguchi H, Koh T et al. Relationships between oxygen and glucose metabolism in human liver tumours: positron emission tomography using (15)O and (18) F-deoxyglucose. Nucl Med Commun. 2004; 25: 577-83.

[35] Stewart EE, Chen X, Hadway J et al. Correlation between hepatic tumor blood flow and glucose utilization in a rabbit liver tumor model. Radiology. 2006; 239: 740-50.